经会阴前列腺穿刺活检中活检标本数与前列腺体积之比(活检密度)大于1.5可提高前列腺癌检出率
研究纳入2家机构436例接受经会阴前列腺定位活检的男性,活检密度为标本总数(平均59.4)与前列腺体积(平均44.9 cc)之比。活检密度>1.5组阳性率84.9% vs ≤1.5组56.4%(OR 1.5,95%CI 1.3-1.7,p<0.001),且更高密度组检出更多Gleason评分6癌症。作者认为活检密度>1.5可使前列腺癌诊断增加1.5倍,应视为经会阴前列腺定位活检的最佳采样方法。
要点
- 活检密度>1.5组前列腺癌阳性率84.9%,≤1.5组为56.4%(OR 1.5,95%CI 1.3-1.7,p<0.001)。
- 活检密度>1.5组检出Gleason评分6癌症94/158(59.5%),≤1.5组为62/141(44.9%)(p=0.007)。
- 回归分析中活检密度(p=0.012)与前列腺特异性抗原(p=0.053)与阳性活检及Gleason评分7+疾病相关。
核心结论
- 活检密度大于1.5可使前列腺癌诊断增加1.5倍,检出更高体积的Gleason评分6疾病,应视为经会阴前列腺定位活检的最佳采样方法。
研究设计与样本
- 共436例男性在2家机构接受经会阴前列腺定位活检。
- 活检密度计算为获取的标本总数(平均59.4)与前列腺体积(平均44.9 cc)之比。
- 采用方差分析和卡方检验评估活检密度与前列腺特异性抗原、前列腺特异性抗原密度、癌症诊断及Gleason评分的关联,并做回归分析确定与阳性活检及Gleason评分7+癌症相关的因素。
主要发现
- 436例中299例(68.6%)经会阴前列腺定位活检阳性。
- 阳性核心平均数为7.1(范围1至41),平均活检密度为1.46(范围0.39至3.67)。
- 阳性与阴性经会阴前列腺定位活检的平均核心数分别为1.61与1.14(p<0.001)。
- 活检密度≤0.5、>0.5至1.0、>1.0至1.5及>1.5对应的阳性活检率分别为25%、37.4%、70.7%和84.9%(p<0.001)。
- 活检密度≤1.5 vs >1.5的阳性活检率为56.4% vs 84.9%(OR 1.5,95%CI 1.3-1.7,p<0.001)。
关键数值与推荐
- 活检密度>1.5组阳性活检率84.9% vs ≤1.5组56.4%(OR 1.5,95%CI 1.3-1.7,p<0.001)。
- 活检密度≤0.5、>0.5至1.0、>1.0至1.5及>1.5组的阳性活检率分别为25%、37.4%、70.7%和84.9%(p<0.001)。
- 更高活检密度组Gleason评分6癌症为94/158(59.5%) vs 较低密度组62/141(44.9%)(p=0.007)。
- 更高活检密度组Gleason评分6的阳性核心数为4.9 vs 较低密度组3.6(p=0.036)。
临床怎么用
- 作者认为活检密度大于1.5应视为经会阴前列腺定位活检的最佳采样方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We sought to determine the minimum number of transperineal prostate mapping biopsies needed to optimize the prostate cancer detection rate. MATERIALS AND METHODS: A total of 436 men underwent transperineal prostate mapping biopsy at 2 institutions. Biopsy density was calculated as the ratio of the total number of specimens retrieved (mean 59.4) to prostate volume (mean 44.9 cc). Associations of biopsy density with prostate specific antigen, prostate specific antigen density, cancer diagnosis and the Gleason score were tested by ANOVA and the chi-square test. Regression analysis was done to determine factors associated with a positive transperineal prostate mapping biopsy and Gleason score 7 or higher cancer. RESULTS: Transperineal prostate mapping biopsy was positive in 299 of 436 men (68.6%). The mean number of positive cores was 7.1 (range 1 to 41) and mean biopsy density was 1.46 (range 0.39 to 3.67). The mean number of cores in positive vs negative transperineal prostate mapping biopsies was 1.61 vs 1.14 (p <0.001). Biopsy density cut points of 0.5 or less, greater than 0.5 to 1.0, greater than 1.0 to 1.5 and greater than 1.5 were associated with positive biopsy in 25%, 37.4%, 70.7% and 84.9% of patients (p <0.001). Dichotomizing biopsy density to 1.5 or less vs greater than 1.5 resulted in a positive biopsy rate of 56.4% vs 84.9% (OR 1.5, 95% CI 1.3-1.7, p <0.001). More Gleason score 6 cancers were diagnosed with higher biopsy density (94 of 158 or 59.5% vs 62 of 141 or 44.9%, p = 0.007). However, the number of positive cores with Gleason score 6 was greater in men with higher biopsy density at 4.9 vs 3.6 (p = 0.036). Prostate specific antigen (p = 0.053) and biopsy density (p = 0.012) were significant on regression analysis for positive transperineal prostate mapping biopsy and Gleason score 7+ disease. CONCLUSIONS: Biopsy density greater than 1.5 increases the diagnosis of prostate cancer by 1.5 times, detects higher volume Gleason score 6 disease and should be considered the optimal sampling approach when performing transperineal prostate mapping biopsy.
引用
- Stone NN, Crawford ED, Skouteris VM, et al. The Ratio of the Number of Biopsy Specimens to Prostate Volume (Biopsy Density) Greater Than 1.5 Improves the Prostate Cancer Detection Rate in Men Undergoing Transperineal Biopsy of the Prostate. J Urol. 2019. PMID: 30835628. doi:10.1097/JU.0000000000000204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。